BBCET

BBCET is a biotechnology company focused on developing next-generation enzyme replacement therapies (ERTs) that can effectively cross the blood-brain barrier (BBB). The company's proprietary platform technology utilizes a specialized transport mechanism to deliver therapeutic enzymes into the central nervous system, addressing the neurological manifestations of lysosomal storage disorders. Their lead programs target rare genetic conditions such as Mucopolysaccharidosis type I (MPS I) and type II (MPS II), where conventional ERTs often fail to reach the brain in therapeutic concentrations. By overcoming the BBB, BBCET aims to provide comprehensive treatment for both systemic and cognitive symptoms of these devastating diseases.